Guardant Health GH Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Total Revenue by Product | ||||||
| Biopharma and data | $217.73M+3.6% | $210.13M+2.2% | $205.64M+4.1% | $197.46M+6.5% | $185.37M+4.4% | |
| Licensing and other | $8.85M+3.3% | $8.56M-4.3% | $8.95M-8.0% | $9.73M-4.6% | $10.19M-24.4% | |
| Oncology | $737.99M+8.0% | $683.6M+6.9% | $639.26M+7.2% | $596.05M+5.0% | $567.64M+4.6% | |
| Screening | $115.65M+45.0% | $79.73M+63.6% | $48.72M+90.2% | $25.62M+137% | $10.8M+111% | |
| Revenue by Geography | ||||||
| International | $65.92M+12.2% | $58.74M+14.6% | $51.24M+9.4% | $46.86M+15.5% | $40.57M-3.1% | |
| United States | $1.01B+9.9% | $923.28M+8.5% | $851.33M+8.9% | $781.99M+6.6% | $733.42M+5.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Guardant Health break its business down?
- Guardant Health (GH) reports total revenue by product across 4 parts — Biopharma and data, Licensing and other, Oncology and Screening. Each is extracted from the segment footnotes and tracked over time.
- Where does Guardant Health's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Guardant Health's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
